Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling. by Arts, Florence et al.
Available at:
http://hdl.handle.net/2078.1/157191
[Downloaded 2019/04/19 at 07:23:48 ]
"Idiopathic basal ganglia calcification-associated
PDGFRB mutations impair the receptor signalling."
Arts, Florence ; Velghe, Amélie ; Stevens, Monique ; Renauld,
Jean-Christophe ; Essaghir, Ahmed ; Demoulin, Jean-Baptiste
Abstract
Platelet-derived growth factors (PDGF) bind to two related receptor tyrosine
kinases, which are encoded by the PDGFRA and PDGFRB genes. Recently,
heterozygous PDGFRB mutations have been described in patients diagnosed
with idiopathic basal ganglia calcification (IBGC or Fahr disease), a rare inherited
neurological disorder. The goal of the present study was to determine whether
these mutations had a positive or negative impact on the PDGFRB activity. We
first showed that the E1071V mutant behaved like wild-type PDGFRB and may
represent a polymorphism unrelated to IBGC. In contrast, the L658P mutant had
no kinase activity and failed to activate any of the pathways normally stimulated by
PDGF. The R987W mutant activated Akt and MAP kinases but did not induce the
phosphorylation of signal transducer and activator of transcription 3 (STAT3) after
PDGF stimulation. Phosphorylation of phospholipase Cγ was also decreased.
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Abstract
Platelet-derived growth factors (PDGF) bind to two related receptor tyrosine kinases, which are encoded by the PDGFRA and PDGFRB genes.
Recently, heterozygous PDGFRB mutations have been described in patients diagnosed with idiopathic basal ganglia calcification (IBGC or Fahr
disease), a rare inherited neurological disorder. The goal of the present study was to determine whether these mutations had a positive or nega-
tive impact on the PDGFRB activity. We first showed that the E1071V mutant behaved like wild-type PDGFRB and may represent a polymor-
phism unrelated to IBGC. In contrast, the L658P mutant had no kinase activity and failed to activate any of the pathways normally stimulated by
PDGF. The R987W mutant activated Akt and MAP kinases but did not induce the phosphorylation of signal transducer and activator of transcrip-
tion 3 (STAT3) after PDGF stimulation. Phosphorylation of phospholipase Cc was also decreased. Finally, we showed that the R987W mutant
was more rapidly degraded upon PDGF binding compared to wild-type PDGFRB. In conclusion, PDGFRB mutations associated with IBGC impair
the receptor signalling. PDGFRB loss of function in IBGC is consistent with recently described inactivating mutations in the PDGF-B ligand.
These results raise concerns about the long-term safety of PDGF receptor inhibition by drugs such as imatinib.
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Introduction
Idiopathic basal ganglia calcification (IBGC), also called Fahr disease,
is a rare neurological disease characterized by symmetrical bilateral
calcifications, which are mostly located in the basal ganglia but can
also be detected in other areas of the brain. The clinical features of
this disease are heterogeneous and include a range of motor and psy-
chiatric disorders such as dementia, parkinsonism, psychosis and
seizures. IBGC is a familial disorder with an autosomal-dominant
inheritance [1, 2]. Until recently, not much was known about the
physiopathology of the disease. Defects in the blood brain barrier
integrity have been observed in one patient [3]. The breakthrough
came only recently from genetic studies in patients and mice. Indeed,
heterozygous mutations in three genes were associated with the dis-
ease: SLC20A2, PDGFB and PDGFRB.
Loss-of-function mutations were first identified in the sodium-
dependent phosphate transporter gene SLC20A2 [4–6]. Mice deficient
in SLC20A2 show brain calcification, indicating a causal relationship
between SLC20A2 mutations and the human disease [7]. Mutations
were also found in PDGFB, which encodes platelet-derived growth
factor B [8]. Although they were not characterized experimentally,
these mutations were predicted to represent loss-of-function alleles.
Homozygous PDGFB deletion in mice is lethal because of a severe
lack of vascular smooth muscle cells and pericytes [9, 10]. In mice
carrying a viable PDGFB hypomorph allele, Keller and colleagues
observed blood brain barrier abnormalities and brain calcification,
which were reminiscent of human IBGC [8]. Interestingly, we have
observed that platelet-derived growth factor (PDGF)-B increases the
expression of SLC20A2 in mesenchymal cell cultures, providing a
possible link between these two genes in IBGC [11].
PDGF-B binds to two related receptor tyrosine kinases (RTK),
PDGF receptor (PDGFR) a and b, which are encoded by the PDGFRA
and PDGFRB genes [9, 12]. PDGFR are divided into three parts: the
extracellular domain which binds the ligand, the a-helix transmembrane
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domain and the intracellular kinase domain [13]. In the absence of
ligand, the kinase domain is auto-inhibited by three cytoplasmic
regions: the juxtamembrane domain, the activation loop of the kinase
domain and the C-terminal tail [13–15]. Both a and b receptors stim-
ulate cell proliferation and migration through an array of signalling
pathways including mitogen-activated protein (MAP) kinases, phos-
phatidylinositol-3 kinase (PI3K), phospholipase Cc (PLCc) and signal
transducers and activators of transcription (STAT) [12, 16]. After
ligand stimulation, the receptors are internalized and degraded in
lysosomes [17].
Various types of genetic alterations activate these two receptors
in cancers of mesenchymal and hematopoietic origin, such as derma-
tofibrosarcoma protuberans, gastrointestinal stromal tumours (GIST),
inflammatory fibroid polyps, glioblastoma and myeloid neoplasms
associated with hypereosinophilia [12, 15, 18]. A germline activating
mutation in PDGFRA was associated with familial GIST [19]. Recently,
PDGFRB mutations were also identified in autosomal-dominant
infantile myofibromatosis, a disease characterized by myofibroblasts
proliferation [20, 21]. Contrasting with these cancer-associated muta-
tions, Nicolas and colleagues found germline PDGFRB mutations in
IBGC [2, 22]. These are the first PDGF receptor mutations identified
in a non-neoplastic disease. The L658P substitution was found in one
family while R987W and E1071V were identified in sporadic cases [2,
22]. The L658 residue is located in the intracellular kinase domain
while R987 and E1071 belong to the C-terminal tail, which regulates
the activity, signalling and endocytosis of the receptor [12, 14]. The
goal of the present study was to characterize the functional impact of
these mutations on the receptor activity.
We show here that the PDGFRb L658P mutant completely abol-
ishes the receptor kinase activity and signalling while the R987W sub-
stitution increases the receptor degradation, leading to deficient
STAT3 signalling. These observations complement the very recent
report of Sanchez-Contreras et al. [23]. Finally, the E1071V mutant
did not present defects consistent with an involvement in IBGC.
Materials and methods
Antibodies, reagents and constructs
Anti-PDGFRb (958) and anti-phosphotyrosine (PY99) antibodies were pur-
chased from Santa Cruz Biotechnology, Dallas, Texas, USA. The anti-
PDGFRb (AH 17.2) monoclonal antibody was produced as described [24].
Anti-phospho-STAT3 (Tyr705), anti-STAT3, anti-phospho-Akt (Ser473),
anti-Akt, anti-phospho-PLCc1 (Tyr783) and anti-PLCc antibodies were
purchased from Cell Signaling Technology, Danvers, MA, USA. Anti-caln-
exin antibody was purchased from Enzo Life Sciences, Farmingdale, NY,
USA. Secondary antibodies used in western blot experiments were pur-
chased from Cell Signaling Technology. The secondary antibody coupled
to phycoerythrin used in flow cytometry was purchased from Jackson Im-
munoResearch, West Grove, PA, USA. Fluorescent secondary antibodies
were purchased from LI-COR Biosciences, Lincoln, NE, USA. PDGF-BB
was purchased from PeproTech, Rocky Hill, NJ, USA. Imatinib was pur-
chased from LC Laboratories (Woburn, MA, USA). Cycloheximide was
purchased from Sigma. ATP was purchased from Fermentas (Thermo
Fisher Scientific, Waltham, MA, USA). EZ-Link Sulfo-NHS-Biotin and strep-
tavidin agarose beads were purchased from Pierce (Thermo Scientific).
Cell culture
The HT-1080 human fibrosarcoma cell line was a kind gift from Ana-
belle Decottignies (de Duve Institute, Brussels) and were cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco, Life Technologies,
Grand Island, NY, USA) supplemented with 10% foetal calf serum
(FCS). MCF7 cells, a human breast adenocarcinoma cell line, and the
human embryonic kidney HEK-293T cells were grown in DMEM (Gibco)
supplemented with 10% FCS.
Site-directed mutagenesis
Wild-type PDGFRb was cloned in pcDNA3.1 (Invitrogen, Life Technolo-
gies). The point mutations L658P, R987W and E1071V were introduced
by site-directed mutagenesis using the QuickChangeTM XL-II kit as rec-
ommended by the manufacturer (Stratagene, La Jolla, CA, USA). All the
constructs were verified by sequencing the whole insert.
Luciferase assays
MCF7 cells were seeded in 6-well plates (300,000 cells/well). The day
after, cells were cotransfected with wild-type PDGFRb or its mutants
(0.5 lg), a luciferase reporter controlled by serum-response elements
(pSRE, 0.5 lg) and pEF1-b-galactosidase (0.5 lg) by using FuGENE
HD Transfection Reagent (Promega, Leiden, The Netherlands). Four
hours after transfection, cells were washed with PBS and fresh medium
was added. PDGF-BB (20 ng/ml) was added in the appropriate wells.
HT-1080 cells were seeded in 12-well plates (150,000–200,000 cells/
well). The day after, cells were cotransfected with wild-type PDGFRb or
its mutants (0.5 lg), a plasmid in which the luciferase expression is
controlled by a STAT1/3/5 sensitive promoter (pGRR5, 0.5 lg) and
pEF1-b-galactosidase (0.5 lg) by using FuGENE HD. Four hours after
transfection, cells were washed with PBS and starved in minimum
essential medium supplemented with 0.05% bovine serum albumin,
50 U/ml penicillin, 50 lg/ml streptomycin and 2 mM glutamine. Cells
were stimulated with PDGF-BB (20 ng/ml) or left untreated.
Twenty-four hours after transfection, cells were lysed and the lucifer-
ase activity was assessed by using GloMax as described [25]. The
b-galactosidase activity was assessed by mixing 40 ll of lysate with
40 ll of substrate solution (165 mM Na2HPO4, 38 mM NaH2PO4, 2 mM
MgCl2, 72 mM b-mercaptoethanol, 4.4 mM o-nitrophenyl-b-D-galacto-
pyranoside) and by measuring the absorbance at 405 nm after 30 min.
The results represent the ratio between luciferase and b-galactosidase
activity. This ratio was set to 100% for stimulated wild-type PDGFRb.
Transfection, selection and sorting of cells
expressing wild-type PDGFRb or its mutants
HT-1080 cells were transfected by using FuGENE HD. The cells were
seeded in 6-well plates at 400,000 cells/well. The day after, the cells were
transfected with PDGFRb wild-type, L658P or R987W (0.5 lg/well). Four
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hours after transfection, cells were washed with PBS and fresh medium
was added. Twenty-four hours after transfection, cells were transferred to
10 cm dishes and treated with 3 mg/ml G418. After amplification in cul-
ture, HT-1080 cells stably expressing wild-type PDGFRb or mutants were
sorted by flow cytometry. For this purpose, cells were first incubated with
an anti-PDGFRb (AH 17.2) antibody (5 lg/ml) for 40 min. at 4°C and then
with a secondary antibody coupled to phycoerythrin for 40 min. at 4°C
and in the dark. These cells were finally sorted by FACSAria III (BD
Biosciences, Erembodegem, Belgium).
Western blot
HT-1080 stably expressing wild-type PDGFRb or the mutants were
seeded in 6-well plates (400,000 cells/well). The day after, cells were
starved overnight. Then, PDGF-BB was added in the appropriate wells
for the indicated periods of time. After washing with PBS, cells were
lysed with a lysis buffer (25 mM Tris, 0.15 M NaCl, 6 mM EDTA,
1.25 M glycerol, 1% Triton X-100, pH 7.4, 1.7 lg/ml aprotinin, 1 mM
Pefabloc and 1 mM sodium orthovanadate). Total cell lysates were cen-
trifuged at 16,000 9 g for 20 min. at 4°C, separated by SDS-PAGE and
transferred on polyvinylidene fluoride membranes. These membranes
were then incubated with the appropriate primary antibody. When indi-
cated, membranes were re-probed with another antibody after stripping
(incubation in 0.4 M NaOH for 8 min.). To visualize the protein of inter-
est, secondary antibodies coupled to horseradish peroxidase were used
and membranes were incubated with Western Blotting Luminol Reagent
Solution A and B (Santa Cruz Biotechnology).
Immunoprecipitation and in vitro phosphorylation
assay
HEK-293T cells were transiently transfected with wild-type PDGFRb or
mutants by using the calcium phosphate method as described [26]. Four
hours after transfection, cells were washed with PBS and new medium
was added. The day after, imatinib (1 lM) was added to the cells for
4 hrs. Cell lysates were produced as described above and incubated with
an anti-PDGFRb (AH 17.2) antibody overnight on wheel at 4°C and then
with Protein A/G UltraLink Resin (Thermo Scientific) for 1 hr 30 on wheel
at 4°C. Beads were washed twice with lysis buffer and once with the
kinase buffer (50 mM HEPES pH 7.6, 50 mM MgCl2). Then, beads were
incubated in 50 ll kinase buffer with or without 50 lM ATP for 10 min. at
30°C. The reaction was stopped by adding 49 Laemmli buffer. Western
blotting experiments were performed as described above. Membranes
incubated with an anti-phosphotyrosine antibody (PY99) were re-probed
with an anti-PDGFRb (958) antibody after stripping. To visualize the pro-
tein of interest, fluorescent secondary antibodies were used (Odyssey;
LI-COR Biosciences) and membranes were analysed with Odyssey Infra-
red Imaging System (LI-COR Biosciences). Results were represented as
the ratio between phospho-PDGFRb and total PDGFRb. This ratio was set
to 100% for wild-type PDGFRb incubated with ATP.
Cell surface protein biotinylation
HT-1080 cells stably expressing wild-type PDGFRb or R987W were
seeded in 6-well plates. The day after, cells were starved in IMDM without
FCS overnight. PDGF-BB (20 ng/ml) was added in the appropriate wells
for 1, 2 or 4 hrs. Then, plates were placed on ice to prevent further endo-
cytosis. After being washed twice in PBS pH 8, cells were incubated with
0.2 mg/ml sulfo-NHS-biotin (Pierce, Thermo Scientific) in PBS pH 8 for
1 hr on ice. Unbound biotin was inactivated by incubation in TBS (50 mM
Tris, 150 mM NaCl, pH 8) for 5 min. Then, HT-1080 cells were washed
twice with TBS and lysed as described above. Biotinylated surface proteins
were immunoprecipitated with streptavidin agarose beads (Pierce, Thermo
Scientific) and the presence of PDGFRb was assessed by western blot.
Results
The L658P and R987W mutations alter PDGFRb
signalling while the E1071V mutation has no
effect
We assessed the impact of the three mutations identified in patients
diagnosed with IBGC (namely L658P, R987W and E1071V) on
PDGFRb signalling using a luciferase reporter assay as described
[25]. MCF7 and HT-1080 cells were transiently transfected with the
empty vector, wild-type PDGFRb or one of the three mutants. Two
signalling pathways known to be activated by wild-type PDGFRb upon
ligand stimulation were analysed by the use of two different reporter
constructs: a promoter containing serum-response elements (pSRE)
which are sensitive to MAP kinase activation, and a GRR5 promoter
driven by STAT transcription factors [25].
The two cell lines did not respond to PDGF, indicating that they
did not express endogenous PDGF receptors (Fig. 1). As expected,
PDGF activated both promoters in cells transfected with wild-type
PDGFRb. By contrast, the L658P mutant did not activate the two
pathways. The R987W mutant was able to activate the MAP kinase
reporter to the same extent as the wild-type receptor in response to
PDGF, but a much decreased STAT response was observed. Unlike
the two first mutations, E1071V did not affect PDGF-induced activa-
tion of the MAP kinase and STAT-driven reporters (Fig. 1). Thus, we
did not analyse this mutant further.
Taken together, our results indicated that the L658P mutation
abolishes PDGFRb signalling, whereas R987W may specifically affect
some signalling pathways.
The L658P mutant is kinase-dead
Given that the L658P mutation is located in the N-terminal lobe of the
kinase domain and that this mutant showed no ability to activate sig-
nalling pathways in luciferase reporter assays, we tested if the substi-
tution had a direct impact on the kinase activity of PDGFRb. For this
purpose, PDGFRb was immunoprecipitated from transiently trans-
fected HEK-293T cells and subjected to an in vitro kinase assay
(Fig. 2A and B). In these settings, prior stimulation by PDGF is not
required to activate the receptor [25].
Autophosphorylation of the wild-type and mutant receptors in
presence of ATP was analysed by western blot (Fig. 2A). Although the
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L658P mutant was expressed to a similar level compared to the wild-
type receptor, it was not phosphorylated on tyrosines in presence of
ATP, demonstrating that it is devoid of kinase activity. By contrast,
the R987W variant was phosphorylated but to a lesser extent com-
pared to the wild-type receptor. Quantification of the blots presented
in Figure 2A suggested that R987W decreased PDGFRb phosphoryla-
tion by about 75% (Fig. 2B).
To further study these mutations, we stably transfected HT-1080
fibrosarcoma cells with wild-type or mutant receptors. The L658P
mutant was expressed at a similar level compared to the wild-type
receptor, as estimated by western blot (Fig. 2C), flow cytometry and
quantitative PCR (Fig. S1). To confirm that L658P causes a loss of
kinase activity, we studied signalling downstream this mutant by wes-
tern blot (Fig. 2C). After PDGF stimulation, the L658P receptor was not
phosphorylated on tyrosines (Fig. 2C), in agreement with the in vitro
kinase assay results. Unlike the wild-type receptor, the L658P variant
was not able to activate Akt, PLCc or STAT3 upon ligand stimulation.
We were not able to analyse Erk1/2 phosphorylation in response to
PDGF because this pathway is constitutively activated in HT-1080 cells
because of the presence of an active N-Ras mutant (data not shown).
Taken together, these results demonstrated that the L658P
mutation completely suppresses the receptor kinase activity and
signalling.
The R987W mutation impairs activation of
PLCc and STAT3 by PDGFRb
We further studied the R987W substitution in stably transfected
HT-1080 cells. Although PDGFRB mRNA levels were comparable, the
cell surface expression of the R987W mutant was slightly lower than
wild-type or L658P, as shown by flow cytometry (Fig. S1). In addi-
tion, the quantification of different western blot experiments showed
that R987W expression was reduced by 29% compared to the wild-
type receptor (n = 13, Student’s t-test, P < 0.001, data not shown).
Phosphorylation of the mutant was similar to the wild-type receptor
in transfected cells.
Our results showed no difference in Akt activation by the two
receptors, whereas PLCc phosphorylation was decreased by about
50% (Fig. 3B). Strikingly, the R987W mutant failed to activate STAT3
in response to PDGF stimulation (Fig. 3A and B), consistent with our
luciferase results.
Altogether, our results demonstrated that mutation R987W selec-
tively impairs PDGFRb signalling, in particular the activation of STAT3
and, to a lesser extent, PLCc but not Akt.
The R987W mutation increases PDGFRb
degradation upon PDGF stimulation
We noticed that the R987W mutant was degraded slightly faster in
response to PDGF after one hour of stimulation (Fig. 3A). In addition,
A
B
Fig. 1 The mutations L658P and R987W, but not E1071V, impair
PDGFRb signalling. (A) MCF7 cells were transfected with plasmids con-
taining the luciferase sequence downstream a SRE promoter, b-galacto-
sidase and PDGFRb wild-type (WT), L658P, R987W or E1071V. Four
hours after transfection, cells were washed and treated or not with
PDGF-BB (20 ng/ml) during 24 hrs. For each condition, luciferase activ-
ity was normalized with b-galactosidase activity. (B) HT-1080 cells were
transfected with a STAT-driven (GRR5) luciferase reporter and pro-
cessed as described above, except that cells were starved during the
stimulation. In both cases, the average of three independent experi-
ments is represented with SEM (Student’s t-test; **P < 0.01;
***P < 0.001).
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the R987W mutation is located about 20 residues downstream a
leucine-rich region that has been involved in ligand-mediated
endocytosis [27].
To study the impact of R987W on the receptor degradation
kinetics, HT-1080 cells stably expressing wild-type PDGFRb or
R987W were stimulated with PDGF for up to 4 hrs and the recep-
tor expression level was assessed by western blot (Fig. 4A and
B). We observed that the R987W mutant was quickly degraded
after PDGF stimulation compared to wild-type PDGFRb. When
cycloheximide was used to block the re-synthesis of the receptor,
this difference was still visible even though it was attenuated
(Fig. 4C and D).
To more precisely assess the level of cell surface receptor, we
performed cell surface protein biotinylation after treatment with
PDGF. Biotinylated proteins were precipitated with streptavidin and
analysed by western blot. Our results suggested that the R987W
mutant was more rapidly internalized compared to the wild-type
receptor (Fig. 4E and F).
In conclusion, these results showed that R987W is more rapidly
degraded upon ligand binding in comparison with the wild-type
receptor.
Discussion
In this study, we demonstrated that the PDGFRB mutations that
have been identified in IBGC lead to a partial or complete loss of
function.
Our results showed that the L658P substitution completely abol-
ished PDGFRb activity. This was observed in three different cell lines
(MCF7, HT-1080 and HEK-293T) in luciferase reporter assays, in vitro
kinase assays and signalling experiments. This mutation has been
identified in all IBGC-diagnosed members of one French family and
was predicted to be damaging [2]. The L658 residue is highly con-
served in PDGFRb from different species and in PDGF receptor family
members. It is located in the N-terminal lobe of the receptor kinase
domain, in which the classical kinase-dead mutation K634A was also
described [28]. The association of PDGFRB loss of function with IBGC
is consistent with a reported role of PDGFRb in cognitive and socio-
emotional disorders based on the analysis of conditional PDGFRB
knock-out mice [29]. Our results are also consistent with previous
studies indicating that loss-of-function mutations in PDGFB, which
encodes the PDGFRb ligand, cause brain calcifications in mice and
A C
B
Fig. 2 The L658P mutant is devoid of kinase activity. (A) 293T cells were transfected with PDGFRb WT, L658P or R987W. After 20 hrs, cells were
treated with imatinib (1 lM) for 4 hrs to prevent phosphorylation. Receptors were immunoprecipitated from cell lysates with an anti-PDGFRb anti-
body and protein A/G beads. The beads were then incubated or not with ATP (50 lM) for 10 min. at 30°C. The phosphorylation level of the recep-
tors was assessed by western blot using an anti-phosphotyrosine antibody. Then, the membrane was re-probed with an anti-PDGFRb antibody. As
a negative control, HEK-293T cells transfected with the empty vector (pcDNA3.1) were used. One representative experiment out of three is shown.
(B) Quantification of the receptor phosphorylation level using an Odyssey instrument. The phosphorylation level was normalized with the total
amount of receptor. The mean of three independent experiments is represented with SD (Student’s t-test; *P < 0.05; ***P < 0.001). (C) Analysis of
the phosphorylation and expression levels of the wild-type receptor and the L658P mutant as well as the phosphorylation of Akt, PLCc and STAT3
upon ligand stimulation. HT-1080 cells stably expressing PDGFRb WT or L658P were washed and starved overnight. Then, cells were treated or not
with PDGF-BB (20 ng/ml) for 15 min. Cell lysates were analysed by western blot. After analysis of the phosphorylated protein, the membrane was
re-probed with an antibody targeting the total amount of the corresponding protein. As a control, untransfected HT-1080 cells were used. Three
independent experiments were performed with similar results. The vertical line indicates that lanes were cropped from the image of the same
western blot membrane.
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IBGC in humans [8, 30]. Altogether, our results indicate that the
L658P mutant encodes a kinase-dead receptor and confirm that it is
responsible for IBGC, as suggested by Sanchez-Contreras et al. [23].
In contrast to L658P, we showed that the E1071V mutation, which
was found in only one sporadic patient, has no negative impact on
PDGF-induced activation of MAP kinases and STAT in luciferase
assays. This residue has been poorly conserved during evolution but
was predicted to be possibly damaging by Polyphen2 and deleterious
by SIFT. It is absent from SNP databases. Nevertheless, it was pre-
dicted to be a polymorphism by Mutation Taster, which is compatible
A B
Fig. 3 The R987W mutant does not activate STAT3. (A) Analysis of the phosphorylation and expression levels of the wild-type receptor and the
R987W mutant as well as the phosphorylation of Akt, PLCc and STAT3 upon ligand stimulation. HT-1080 cells stably expressing PDGFRb WT or
R987W were washed and starved overnight. Then, cells were treated or not with PDGF-BB (20 ng/ml) for 5, 15, 30 and 60 min. Cell lysates were
analysed by western blot. After analysis of the phosphorylated protein, the membrane was re-probed with an antibody targeting the total amount of
the corresponding protein. One representative experiment out of three is shown. (B) The percentage of PDGFRb, Akt, PLCc and STAT3 phosphoryla-
tion was quantified using the ImageJ software. The level of phosphorylation was normalized with the expression of the corresponding protein. The
phosphorylation level of each protein was set to 100% for PDGFRb WT-expressing cells stimulated with PDGF during 15 min. The average of three
independent experiments is shown with SD (ANOVA, P < 0.05 for p-PDGFRb, not significant for p-Akt, P < 0.001 for p-PLCc, P < 0.001 for p-STAT3).
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with our results [22]. The E1071V residue is located in a proline- and
glutamic acid-rich region of the C-terminal tail that we have previously
characterized as a negative regulator of the receptor activity. It is
involved in the auto-inhibition of the receptor in absence of ligand
[14]. If this model is correct, E1071V could increase the receptor
activity. Indeed, in our luciferase reporter assays, the MAP kinase
reporter was more strongly activated by E1071V than by wild-type
PDGFRb, although this did not reach statistical significance. Taken
together, these data do not support the hypothesis that the E1071V
mutation causes IBGC.
Unlike the L658P substitution, the R987W mutation, which is
located outside the kinase domain, did not abolish the kinase activity.
Nevertheless, this activity was decreased in an in vitro assay.
However, this decrease was not confirmed in intact cells, as the tyro-
sine-phosphorylation of the mutant receptor was not affected in the
HT-1080 cell line and signalling via Akt and MAP kinases was
unchanged.
After PDGF stimulation, R987W was more rapidly internalized and
degraded than the wild-type receptor. In addition, in the absence of
exogenously added PDGF, the R987W receptor was expressed at a
A B
C D
E F
Fig. 4 The R987W mutant is more rapidly internalized and degraded than the wild-type receptor. (A) HT-1080 cells stably expressing PDGFRb or the
R987W mutant were washed and starved overnight. Then, cells were treated with PDGF-BB (20 ng/ml) for 1, 2 or 4 hrs or left untreated. Cell
lysates were analysed by western blot with an anti-PDGFRb antibody. As a loading control, the membrane was re-probed with an anti-calnexin anti-
body. Three independent experiments were performed and a representative one is shown here. (B) The amount of PDGFRb was quantified by using
the ImageJ software and was normalized with calnexin expression. The average of three independent experiments is represented with SD (ANOVA,
P < 0.001). (C) The same experiment as in A was performed, except that cells were treated with cycloheximide (CHX, 50 lg/ml) in addition to PDGF
(20 ng/ml). (D) The amount of PDGFRb was quantified by using the ImageJ software and was normalized with calnexin expression. The average of
three independent experiments is represented with SD (ANOVA, P < 0.001). (E) HT-1080 cells stably expressing PDGFRb or the R987W mutant were
washed, starved overnight and treated or not with PDGF-BB (20 ng/ml) during 1, 2 or 4 hrs. Cells were incubated with sulfo-NHS-biotin and biotiny-
lated cell surface proteins were precipitated with streptavidin agarose. The presence of PDGFRb was assessed by western blot. One representative
experiment out of three is shown. (F) Quantification of the amount of cell surface PDGFRb by using the ImageJ software. The average of three inde-
pendent experiments is shown with SD (ANOVA, P < 0.001). In each quantification (B, D and F), the PDGFRb amount was set to 100% for unstimu-
lated PDGFRb WT- and R987W-expressing cells.
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slightly lower level in HT-1080 cells, as shown by flow cytometry and
western blot experiments. This was not because of a difference in
transfection efficiency as mRNA levels were similar. This was not
observed in transiently transfected HEK-293T or HeLa cells (Fig. 2A
and data not shown). These results may be explained by previous
reports showing that HT-1080 cells constitutively secrete PDGF [31].
Accordingly, we observed a slight constitutive phosphorylation of the
receptors in western blot experiments (data not shown). These
results apparently contradict a recent report by Sanchez-Contreras
et al., who suggested that the R987W mutation severely decreased
the receptor expression in HeLa cells in the absence of exogenous
PDGF [23]. This might be related to the use of cell lines of different
origins. Finally, the mechanism whereby this substitution affects the
receptor degradation remains to be established. Noteworthy, the
R987 residue, which is conserved in different species of mammals
and fish as well as in FLT3, is located downstream a region that was
identified as important for PDGFRb ligand-mediated endocytosis
[27]. Indeed, the deletion of this region abolished the receptor inter-
nalization after PDGF stimulation. Thus, a mutation near this region
could affect PDGFRb endocytosis [27]. In addition, the C-terminal tail
is involved in the recruitment of c-CBL (Casitas B-lineage lymphoma)
through a mechanism that remains controversial [32, 33]. c-CBL is
an ubiquitin ligase involved in PDGFR endocytosis and degradation
through lysosomes. The R987W substitution could favour the activa-
tion of c-CBL, leading to an increase in receptor degradation [32].
Strikingly, the R987W mutation selectively impaired STAT3 activa-
tion by PDGF. The mechanism of STAT3 activation by PDGF remains
elusive [12]. In particular, no direct docking site has been described
in the receptor. Interestingly, one study suggested that STAT3 activa-
tion by PDGF requires the receptor internalization, allowing efficient
STAT3 phosphorylation from endosomes [34]. This was also reported
for other RTK such as Met [35]. Therefore, we hypothesize that
R987W may prevent STAT3 activation by perturbing the receptor
internalization and degradation pathway. Similarly, PLCc phosphoryla-
tion, which was reduced by the R987W mutation, can also occur in
endosomes [36]. Furthermore, PLCc binds to residues Y1009 and
Y1021, in the C-terminal tail [16]. The R987W substitution could
cause a change in the C-terminal tail conformation that could
decrease its accessibility or its phosphorylation on these tyrosines.
Y1021 is also one of the proposed binding sites for FER, a tyrosine
kinase that was recently involved in STAT3 activation [37]. In conclu-
sion, the R987W mutation in the C-terminal tail could selectively affect
the docking of PLCc and FER to the PDGFRb receptor, explaining the
impact of this variant on some but not all PDGFR signalling pathways.
An important function of STAT3 downstream the PDGF receptor b
was suggested in vascular smooth muscle cells, which are likely to
play a key role in IBGC. Indeed, STAT3 activation is necessary for the
expression of the cytosolic phospholipase A2 and, subsequently, for
cell growth and motility [38, 39]. In another report on the same cell
type, it was shown that STAT3 inhibition by glutathione S-transferase
is followed by a decrease in PDGF-induced proliferation [40]. These
reports suggest a mechanism whereby a specific STAT3 impairment
could link PDGFRB loss-of-function mutations to IBGC.
Idiopathic basal ganglia calcification is the first disease caused by
loss-of-function PDGFR mutations, by contrast to the numerous
activating mutations described in cancer-related disorders. Somatic
PDGFRA loss-of-function mutations were recently characterized in
cancers, but they likely represent passenger mutations that are not
clinically relevant [25]. Interestingly, the three variants (L658P,
R987W and E1071V) are located outside the two main hot spots of
activating point mutations involved in cancer: the juxtamembrane
domain and the activation loop [15]. However, L658 residue is located
in a region where novel PDGFRb point mutations were identified in
infantile myofibromatosis [20, 21]. These mutations have not been
functionally studied yet but are likely to increase PDGF receptor
signalling.
Currently, patients with GIST or myeloid neoplasms involving
PDGFR gene alterations are successfully treated with imatinib [15,
18]. Imatinib and other tyrosine kinase inhibitors are also adminis-
tered for chronic myeloid leukaemia and other neoplasms. Relapse
frequently occurs upon treatment discontinuation and patient should
keep taking imatinib for very long periods of time [41, 42]. Since the
introduction of the drug, some patients have been treated for more
than 10 years. The observation that inactivation of PDGFRb can lead
to brain calcification and IBGC raises concerns about the long-term
safety of tyrosine kinase inhibitors that target this receptor. To our
knowledge, symptoms like those observed in IBGC have not been
documented yet but this should be carefully monitored in the future.
In conclusion, we showed that PDGFRB mutations associated
with IBGC affect the receptor activity, degradation and signalling.
These results support the current hypothesis that a defect in the
PDGF-B/PDGFRB pathway can cause IBGC. Furthermore, these find-
ings have consequences for the follow-up of long-term treatment with
tyrosine kinase inhibitors and could pave the way for the development
of a treatment for IBGC.
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